xtx301
·Code: XTX301
xtx301: sourced relationships with 1 company · 1 clinical trial tracked.
xtx301 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect xtx301 to XLO; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could xtx301 → XLO affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Xilio Therapeutics, Inc. (XLO) | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors
Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs) (Part 1A only)
Interventionalopen358 targetStarted 2023-05Completion 2028-0912 sites · United StatesXilio Development, Inc.
Frequently asked questions
Which companies have sourced relationships with xtx301?
xtx301 has dated SEC/FDA relationship records for Xilio Therapeutics, Inc..
How many clinical trials involve xtx301?
BioSniper tracks 1 clinical trial involving xtx301.